A combination comprising a first constituent and a second constituent, wherein the first constituent is a chaperon having the ability to rearrange a lysosomal protein, wherein the lysosomal protein has a reduced activity and wherein the chaperon is an imino sugar selected from the group consisting of 1-deoxygalactonojirimycin, alpha-galacto-homonojirimycin, alpha-allo-homonojirimycin, beta-1-C-butyl-deoxygalactonojirimycin, beta-1-C-butyl-deoxynojirimycin, N-nonyl-deoxynojirimycin (NN-DNJ), N-octyl-2,5-anhydro-2,5-imino-D-glucitol, N-octyl-isofagomine, Isofagomine, calystegine A3, calystegine B1, calystegine B2, calystegine C1, 1,5-dideoxy-1,5-iminoxylitol, alpha-1-C-nonyl-DIX, alpha-1-C-octyl-1-DNJ, N-acetyl-glucosamine-thiazoline, 6-acetamido-6-deoxycastanospermine (ACAS), N-butyl-DNJ, Deoxynojirimycin, 2-Acetamido-1,2-dideoxynojirimycin (AdDNJ), N-dodecyl-DNJ, 6-nonyl-isofagomine, N-methyl calystegine A 3, 4-epi-isofagomine, 1-deoxynojirimycin, alpha-homonojirimycin, castanospermine, 1-deoxymannojirimycin, Swainsonine, 2-hydroxy-isofagomine, 1-deoxyfuconojirimycin, beta-homofuconojirimycin, 2,5-imino-1,2,5-trideoxy-L-glucitol, 2,5-dideoxy-2,5-imino-D-fucitol, 2,5-imino-1,2,5-trideoxy-D-altritol, 1,2-dideoxy-2-N-acetamido-nojirimycin, 1,2-dideoxy-2-N-acetamido-galaconojirimycin, 2-N-acetylamino-isofagomine, 1,2-dideoxy-2-acetamido-nojirimycin, 2-N-acetamido-isofagomine, 1,2-dideoxy-2-acetamido-nojirimycin, 1-deoxyiduronojirimycin, 2-carboxy-3,4,5-trideoxypiperidine, 6-carboxy-isofagomine, 2,6-dideoxy-2,6-imino-sialic acid, and Castanospermine; and pharmaceutically acceptable salts thereof; and wherein the second constituent is Ambroxol or a pharmaceutically acceptable salt thereof, bromhexine or a pharmaceutically acceptable salt thereof, a compound of the formula or a pharmaceutically acceptable salt thereof, a compound of the formula or a pharmaceutically acceptable salt thereof, a compound of formula or a pharmaceutically acceptable salt thereof, a compound of formula or a pharmaceutically acceptable salt thereof, a compound of formula (VIII) or a pharmaceutically acceptable salt thereof, and/or a compound of formula or a pharmaceutically acceptable salt thereof. wherein the first constituent is a chaperon having the ability to rearrange a lysosomal protein, wherein the lysosomal protein has a reduced activity and wherein the chaperon is an imino sugar selected from the group consisting of 1-deoxygalactonojirimycin, alpha-galacto-homonojirimycin, alpha-allo-homonojirimycin, beta-1-C-butyl-deoxygalactonojirimycin, beta-1-C-butyl-deoxynojirimycin, N-nonyl-deoxynojirimycin (NN-DNJ), N-octyl-2,5-anhydro-2,5-imino-D-glucitol, N-octyl-isofagomine, Isofagomine, calystegine A3, calystegine B1, calystegine B2, calystegine C1, 1,5-dideoxy-1,5-iminoxylitol, alpha-1-C-nonyl-DIX, alpha-1-C-octyl-1-DNJ, N-acetyl-glucosamine-thiazoline, 6-acetamido-6-deoxycastanospermine (ACAS), N-butyl-DNJ, Deoxynojirimycin, 2-Acetamido-1,2-dideoxynojirimycin (AdDNJ), N-dodecyl-DNJ, 6-nonyl-isofagomine, N-methyl calystegine A 3, 4-epi-isofagomine, 1-deoxynojirimycin, alpha-homonojirimycin, castanospermine, 1-deoxymannojirimycin, Swainsonine, 2-hydroxy-isofagomine, 1-deoxyfuconojirimycin, beta-homofuconojirimycin, 2,5-imino-1,2,5-trideoxy-L-glucitol, 2,5-dideoxy-2,5-imino-D-fucitol, 2,5-imino-1,2,5-trideoxy-D-altritol, 1,2-dideoxy-2-N-acetamido-nojirimycin, 1,2-dideoxy-2-N-acetamido-galaconojirimycin, 2-N-acetylamino-isofagomine, 1,2-dideoxy-2-acetamido-nojirimycin, 2-N-acetamido-isofagomine, 1,2-dideoxy-2-acetamido-nojirimycin, 1-deoxyiduronojirimycin, 2-carboxy-3,4,5-trideoxypiperidine, 6-carboxy-isofagomine, 2,6-dideoxy-2,6-imino-sialic acid, and Castanospermine; and pharmaceutically acceptable salts thereof; and wherein the second constituent is Ambroxol or a pharmaceutically acceptable salt thereof,